219 related articles for article (PubMed ID: 19892405)
1. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?
Heindl LM; Hofmann TN; Adler W; Knorr HL; Holbach LM; Naumann GO; Kruse FE; Cursiefen C
Ophthalmology; 2010 Feb; 117(2):334-42. PubMed ID: 19892405
[TBL] [Abstract][Full Text] [Related]
2. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma.
Mäkitie T; Summanen P; Tarkkanen A; Kivelä T
Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2471-80. PubMed ID: 10509639
[TBL] [Abstract][Full Text] [Related]
3. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma.
Straume O; Jackson DG; Akslen LA
Clin Cancer Res; 2003 Jan; 9(1):250-6. PubMed ID: 12538477
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma.
Mäkitie T; Summanen P; Tarkkanen A; Kivelä T
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1414-21. PubMed ID: 11381040
[TBL] [Abstract][Full Text] [Related]
5. Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance.
Kivelä T; Eskelin S; Mäkitie T; Summanen P
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2085-93. PubMed ID: 11481276
[TBL] [Abstract][Full Text] [Related]
6. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma.
Mäkitie T; Carpén O; Vaheri A; Kivelä T
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2442-9. PubMed ID: 11581181
[TBL] [Abstract][Full Text] [Related]
7. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin.
Cursiefen C; Schlötzer-Schrehardt U; Küchle M; Sorokin L; Breiteneder-Geleff S; Alitalo K; Jackson D
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2127-35. PubMed ID: 12091407
[TBL] [Abstract][Full Text] [Related]
8. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.
Blom DJ; Luyten GP; Mooy C; Kerkvliet S; Zwinderman AH; Jager MJ
Invest Ophthalmol Vis Sci; 1997 Aug; 38(9):1865-72. PubMed ID: 9286277
[TBL] [Abstract][Full Text] [Related]
9. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer.
Bono P; Wasenius VM; Heikkilä P; Lundin J; Jackson DG; Joensuu H
Clin Cancer Res; 2004 Nov; 10(21):7144-9. PubMed ID: 15534085
[TBL] [Abstract][Full Text] [Related]
10. [Diffuse malignant melanoma of the uvea. A clinico-histopathologic study of 39 patients].
Braun UC; Rummelt VC; Naumann GO
Klin Monbl Augenheilkd; 1998 Dec; 213(6):331-40. PubMed ID: 10048010
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
[TBL] [Abstract][Full Text] [Related]
12. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma.
Clarijs R; Schalkwijk L; Ruiter DJ; de Waal RM
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1422-8. PubMed ID: 11381041
[TBL] [Abstract][Full Text] [Related]
13. HLA expression in choroidal melanomas: correlation with clinicopathological features.
Krishnakumar S; Abhyankar D; Lakshmi SA; Pushparaj V; Shanmugam MP; Biswas J
Curr Eye Res; 2004 Jun; 28(6):409-16. PubMed ID: 15512948
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas.
Isager P; Ehlers N; Overgaard J
Acta Ophthalmol Scand; 2004 Oct; 82(5):517-25. PubMed ID: 15453846
[TBL] [Abstract][Full Text] [Related]
15. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.
Dadras SS; Paul T; Bertoncini J; Brown LF; Muzikansky A; Jackson DG; Ellwanger U; Garbe C; Mihm MC; Detmar M
Am J Pathol; 2003 Jun; 162(6):1951-60. PubMed ID: 12759251
[TBL] [Abstract][Full Text] [Related]
16. Lymphangiogenesis in tumors: what do we know?
Reis-Filho JS; Schmitt FC
Microsc Res Tech; 2003 Feb; 60(2):171-80. PubMed ID: 12539171
[TBL] [Abstract][Full Text] [Related]
17. Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1).
Trojan L; Michel MS; Rensch F; Jackson DG; Alken P; Grobholz R
J Urol; 2004 Jul; 172(1):103-7. PubMed ID: 15201747
[TBL] [Abstract][Full Text] [Related]
18. Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension.
Gündüz K; Shields CL; Shields JA; Cater J; Brady L
Am J Ophthalmol; 2000 Jul; 130(1):97-102. PubMed ID: 11004266
[TBL] [Abstract][Full Text] [Related]
19. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis.
Jackson DG
APMIS; 2004; 112(7-8):526-38. PubMed ID: 15563314
[TBL] [Abstract][Full Text] [Related]
20. Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body.
Al-Jamal RT; Mäkitie T; Kivelä T
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2381-9. PubMed ID: 12766034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
